Patient baseline characteristics
| Characteristics . | N = 48 . |
|---|---|
| Median age (range), y | 64.5 (37.0-85.0) |
| Male, n (%) | 29 (60.4) |
| ECOG PS, n (%) | |
| 0 | 26 (54.2) |
| 1 | 22 (45.8) |
| Median number of previous lines of systemic therapy (range) | 3 (1-12) |
| Previous therapy, n (%) | |
| Anti-CD20 antibody | 48 (100) |
| Chemotherapy and anti-CD20 antibody | 43 (89.6) |
| PI3K inhibitor | 17 (35.4) |
| Lenalidomide | 14 (29.2) |
| Autologous stem cell transplant | 6 (12.5) |
| cBTKi | 4 (8.3) |
| CAR T-cells | 4 (8.3) |
| BCL2 inhibitor | 3 (6.3) |
| Other systemic therapy∗ | 18 (37.5) |
| FLIPI risk group, n (%) | |
| Low (0-1) | 9 (18.8) |
| Intermediate (2) | 14 (29.2) |
| High (3-5) | 22 (45.8) |
| Missing | 3 (6.3) |
| Involved nodal sites, n (%) | |
| ≤4 | 27 (56.3) |
| >4 | 19 (39.6) |
| Missing | 2 (4.2) |
| Tumor bulk (cm), n (%) | |
| <5 | 33 (68.8) |
| ≥5 | 10 (20.8) |
| No measurable lymph node | 5 (10.4) |
| Ann Arbor staging, n (%) | |
| I/II | 8 (16.7) |
| III/IV | 39 (81.3) |
| Missing | 1 (2.1) |
| Baseline LDH > ULN, n (%) | |
| Yes | 14 (29.2) |
| No | 34 (70.8) |
| Baseline hemoglobin of <120 g/L, n (%) | |
| Yes | 14 (29.2) |
| No | 34 (70.8) |
| Characteristics . | N = 48 . |
|---|---|
| Median age (range), y | 64.5 (37.0-85.0) |
| Male, n (%) | 29 (60.4) |
| ECOG PS, n (%) | |
| 0 | 26 (54.2) |
| 1 | 22 (45.8) |
| Median number of previous lines of systemic therapy (range) | 3 (1-12) |
| Previous therapy, n (%) | |
| Anti-CD20 antibody | 48 (100) |
| Chemotherapy and anti-CD20 antibody | 43 (89.6) |
| PI3K inhibitor | 17 (35.4) |
| Lenalidomide | 14 (29.2) |
| Autologous stem cell transplant | 6 (12.5) |
| cBTKi | 4 (8.3) |
| CAR T-cells | 4 (8.3) |
| BCL2 inhibitor | 3 (6.3) |
| Other systemic therapy∗ | 18 (37.5) |
| FLIPI risk group, n (%) | |
| Low (0-1) | 9 (18.8) |
| Intermediate (2) | 14 (29.2) |
| High (3-5) | 22 (45.8) |
| Missing | 3 (6.3) |
| Involved nodal sites, n (%) | |
| ≤4 | 27 (56.3) |
| >4 | 19 (39.6) |
| Missing | 2 (4.2) |
| Tumor bulk (cm), n (%) | |
| <5 | 33 (68.8) |
| ≥5 | 10 (20.8) |
| No measurable lymph node | 5 (10.4) |
| Ann Arbor staging, n (%) | |
| I/II | 8 (16.7) |
| III/IV | 39 (81.3) |
| Missing | 1 (2.1) |
| Baseline LDH > ULN, n (%) | |
| Yes | 14 (29.2) |
| No | 34 (70.8) |
| Baseline hemoglobin of <120 g/L, n (%) | |
| Yes | 14 (29.2) |
| No | 34 (70.8) |
Data cutoff of 27 January 2025.
BCL2, B-cell lymphoma 2; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; PI3K, phosphoinositide 3-kinase; ULN, upper limit of normal.
Other systemic therapies include: histone deacetylase inhibitors, radioimmunotherapy, anti-CD74 antibodies, and proteasome inhibitors